Skip to main content
SpringerLink
Log in

Risks of incretin-based drugs in patients with T2DM examined

  • Review
  • Published:
Reactions Weekly Aims and scope

This is a preview of subscription content, log in via an institution to check access.

Access this article

Log in via an institution

Price excludes VAT (USA)
Tax calculation will be finalised during checkout.

Instant access to the full article PDF.

Institutional subscriptions

References

  • Bolen SD, et al. The safety of incretin based drug treatments for type 2 diabetes. BMJ 352: [2 pages], 17 Feb 2016. Available from: URL: http://dx.doi.org/10.1136/bmj.i801

  • Azoulay L, et al. Incretin based drugs and the risk of pancreatic cancer: international multicentre cohort study. BMJ 352: [8 pages], 17 Feb 2016. Available from: URL: http://dx.doi.org/10.1136/bmj.i581

  • Li L, et al. Dipeptidyl peptidase-4 inhibitors and risk of heart failure in type 2 diabetes: systematic review and meta-analysis of randomised and observational studies. BMJ 352: [17 pages], 17 Feb 2016. Available from: URL: http://dx.doi.org/10.1136/bmj.i610

Download references

Rights and permissions

Reprints and permissions

About this article

Check for updates. Verify currency and authenticity via CrossMark

Cite this article

Risks of incretin-based drugs in patients with T2DM examined. Reactions Weekly 1590, 10 (2016). https://doi.org/10.1007/s40278-016-15062-4

Download citation

  • Published:

  • Issue Date:

  • DOI: https://doi.org/10.1007/s40278-016-15062-4

Search

Navigation